|
Title of
Clinical Trial |
Species |
Investigator |
|
Canine
Osteosarcoma Study
Eligible
dogs must have been diagnosed with
osterosarcoma by either cytologically or
histologically. Patients with local,
regional, or systemic metastatic disease are
eligible for treatment. Patients with an
anticipated survival time without treatment
of more than 2 months are required.
In this
study, dogs diagnosed with osteosarcoma are
invited to participate. The participant
patient will be treated with amputation,
IL-12 and standard chemotherapy treatment.
IL-12 administration via electroporation
will be performed 2-7 days prior to and 2-7
days post surgery. If you are not satisfied
with the outcome, you can withdraw your pet
from the clinical trial anytime. The
participant patients will be anesthetized
through LSU-SVM anesthesia service for
performing the treatment, including
injection of the immune stimulator via
electroporation. Needles will be inserted
into tumors for injection and
electroporation. The electroporation lasts
for less than one second and the whole
procedure last for less than 5 minutes once
dogs are under anesthesia. A total of two
IL-12 administrations via electroporation
will be performed. Prior to both the first
and the second IL-12 administration, blood
will be drawn for CBC, serum chemistry
profile, and cytokine profile analysis. A
follow-up check will be performed one week
after the second treatment. Carbplatin (a
standard chemotherapy drug) will be
administered every 3 weeks, and a total of
five doses will be administered. A follow-up
recheck will be performed every other month
after completion of the chemotherapy
protocol.
|
canine |
Dr
Keijiro Shiomitsu
Dr Shulin Li |
|
Establishment
of a technique for transesophageal
echocardiogram in birds |
avian |
Dr
Tom Tully |
|
Contrast harmonic ultrasound imaging of the
normal pancreas and pancreatitis in dogs |
canine |
Dr
Lorrie Gaschen |
|
Altered intercellular communication,
arrhythmias, and sudden death in Boxer dogs |
canine |
Dr Romain Pariaut |
|
IL12 gene
therapy for enhancing therapeutic efficacy of
bleomycin against oral tumors in owners’ dogs |
canine |
Dr Shulin Li |
|
Contrast harmonic and spectral Doppler
ultrasound imaging of visceral lymph nodes in
dogs |
canine |
Dr
Lorrie Gaschen |
|
Use of contrast-enhanced harmonic ultrasound for
differentiating benign versus malignant liver
nodules in dogs |
canine |
Dr
Lorrie Gaschen |
|
Characterization of CSF lactate concentrations
in dogs evaluated for neurologic disease |
canine |
Dr Isabelle Cattin |
|
Characterization of plasma matrix
metalloproteinase-2 and -9 activities in dogs
with naturally occurring mitral valve disease |
canine |
Dr Romain Pariaut |
|
Mitoxantrone vs. Mitoxantrone + DTIC for dogs
with refractory lymphoma |
canine |
Dr Tracy Gieger |
|
Comet-tail artifacts in normal dogs and dogs
with cardiogenic pulmonary edema |
canine |
Dr Nathalie Rademacher
Dr Romain Pariaut |
|
Comparison of passive range of motion achieved
by owners instructed with different teaching
modalities versus trained veterinary personnel |
canine |
Dr Erica Hartmann |
|
Comparison of ultrasound biometry and automatic
keratometry for determination of corneal
curvature in dogs |
canine |
Dr. Renee Carter |
|
Equine stem cell therapy for tendon and
ligament injuries |
equine |
Dr Jill Johnson |
|
An evaluation of the clinical efficacy of
pergolide mesylate tablets for the control of
clinical signs associated with pituitary pars
intermedia dysfunction (equine Cushing’s
disease) in horses |
equine |
Dr Frank
Andrews |
|
Development of 2D-PAGE protein maps for healthy
and chronic renal failure cats |
feline |
Dr
Mark Acierno |
|
Use of contrast harmonic ultrasound imaging for
the diagnosis and differentiation of pancreatic
diseases in cats |
feline |
Dr Nathalie Radamacher |
|
Role of acute phase proteins in feline chronic
kidney disease |
feline |
Dr
Mark Acierno |
|
Use of HMG CoA reductase inhibitors for the
treatment of chronic kidney disease in dogs |
feline |
Dr
Mark Acierno |
